ChitogenX partners with Polytechnique Montréal on federal grant for ORTHO-R regenerative treatment
(via NewsDirect)
ChitogenX CEO Phil Deschamps joined Proactive's Natalie Stoberman with news of the company's latest federal grant and partnership deal with Polytechnique Montréal to expand the ORTHO- R platform in regenerative medicine.
Deschamps said the company has obtained a $3,472,000 grant from The Natural Sciences and Engineering Research Council of Canada (NSERC) and Prima Québec and will collaborate with Polytechnique Montréal throughout the four-year grant period to advance the scientific development, expand the scope of indications, develop new biomaterials for regenerative medicine and accelerate the commercial readiness of its flagship ORTHO-R technology platform.
Contact Details
Proactive Canada
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
This email was sent to you at brittanymcnabb17@gmail.com by Stockwatch (www.stockwatch.com) as part of your package of Stockwatch services, and in accordance with your email preferences on file. You may unsubscribe at any time, or change your email preferences within Your Account settings at the Stockwatch website. THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY. You may contact Stockwatch by email at webmaster@stockwatch.com, by phone at 1-800-268-6397 (1-604-687-1500), or by mail to Stockwatch, PO Box 10371, 700 West Georgia Street, Vancouver, BC, V7Y 1J6, Canada. "Stockwatch" is a registered trademark of Canjex Publishing Ltd. Copyright © 2023, Canjex Publishing Ltd. All rights reserved.
